DiaMedica Therapeutics Inc. (DMAC) Financial Ratios
22 years of historical data (2004–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
4.90
↑+45% vs avg
5yr avg: 3.39
30Y Low1.3·High37.1
ROE
↓
-67.7%
↑-39% vs avg
5yr avg: -48.5%
30Y Low-417%·High-36%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
DMAC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
DiaMedica Therapeutics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $315M | $374M | $219M | $92M | $42M | $77M | $159M | $58M | $23M | $30M | $10M |
| Enterprise Value | $300M | $359M | $217M | $88M | $38M | $73M | $152M | $54M | $6M | $28M | $9M |
| P/E Ratio → | -8.36 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | 45.07 | — | — |
| P/B Ratio | 4.90 | 6.66 | 5.39 | 1.81 | 1.31 | 1.76 | 6.11 | 7.63 | 1.32 | 37.15 | 8.36 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
DMAC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | 11.47 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
DMAC Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -67.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | 100.0% | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | -1352.2% | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | -1146.8% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -67.7% | -67.7% | -53.3% | -46.8% | -36.1% | -38.8% | -73.1% | -86.4% | -64.3% | -416.6% | -26983.2% |
| ROA | -60.8% | -60.8% | -48.6% | -43.8% | -34.2% | -36.9% | -66.2% | -77.8% | -56.9% | -231.8% | -212.2% |
| ROIC | -65.5% | -65.5% | -47.1% | -42.8% | -31.4% | -35.2% | -84.2% | -420.3% | -2253.7% | — | — |
| ROCE | -70.8% | -70.8% | -57.8% | -50.9% | -36.7% | -38.9% | -75.1% | -93.6% | -75.8% | -442.0% | -1226.5% |
DMAC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $16M exceeds total debt of $240000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.02 | 0.00 | — | 0.16 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.27 | -0.07 | -0.08 | -0.13 | -0.11 | -0.28 | -0.49 | -0.99 | -1.69 | -1.23 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | -44.41 |
Net cash position: cash ($16M) exceeds total debt ($240000)
DMAC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
DiaMedica Therapeutics Inc.'s current ratio of 11.81x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 19.27x to 11.81x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.81 | 11.81 | 8.28 | 19.27 | 15.61 | 29.82 | 13.77 | 6.70 | 13.87 | 1.49 | 2.96 |
| Quick Ratio | 11.81 | 11.81 | 8.28 | 19.27 | 15.61 | 29.82 | 13.77 | 6.70 | 13.87 | 1.49 | 2.96 |
| Cash Ratio | 11.67 | 11.67 | 8.19 | 18.99 | 15.45 | 29.60 | 13.56 | 5.98 | 12.98 | 1.35 | 2.77 |
| Asset Turnover | — | — | — | — | — | — | — | — | 0.03 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | 471.58 | — | — |
DMAC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
DiaMedica Therapeutics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $47M | $40M | $33M | $26M | $21M | $16M | $12M | $8M | $6M | $5M |
Peer Comparison
Compare DMAC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 DMACYou | $315M | -8.4 | — | — | — | — | -67.7% | -65.5% | — |
 ATHA | $17M | -0.2 | — | — | — | — | -290.8% | — | — |
 ACMR | $7B | 80.2 | 54.2 | — | 44.4% | 12.1% | 6.2% | 7.0% | 2.4 |
 NERV | $31M | -0.1 | — | — | — | — | — | — | — |
 ANIK | $193M | -19.0 | — | 44.3 | 56.6% | -9.8% | -7.3% | -7.1% | — |
 PRAX | $8B | -20.9 | — | — | — | — | -45.8% | -65.0% | — |
 BIIB | $29B | 22.3 | 11.7 | 14.2 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 ACAD | $4B | 9.4 | 25.7 | 35.2 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.8 | 6.8 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 RARE | $3B | -4.7 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 NKTR | $1B | -6.3 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 22 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
DMAC — Frequently Asked Questions
Quick answers to the most common questions about buying DMAC stock.
What is DiaMedica Therapeutics Inc.'s P/E ratio?
DiaMedica Therapeutics Inc.'s current P/E ratio is -8.4x. This places it at the 50th percentile of its historical range.
What is DiaMedica Therapeutics Inc.'s ROE?
DiaMedica Therapeutics Inc.'s return on equity (ROE) is -67.7%. The historical average is -120.6%.
Is DMAC stock overvalued?
Based on historical data, DiaMedica Therapeutics Inc. is trading at a P/E of -8.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.